New Proteins in Body Fluids as Potential Biomarker for Alzheimer's Disease: a Pilot Study
NCT ID: NCT01773915
Last Updated: 2014-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
20 participants
OBSERVATIONAL
2012-12-31
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
New Biomarker for Alzheimer's Disease Diagnostic
NCT01315639
Relationship Between Protein Biomarkers in Cerebrospinal Fluid and Alzheimer&Apos;s Disease in Patients With Depression
NCT02303158
Study to Evaluate Amyloid in Blood and Imaging Related to Dementia
NCT03899844
FluoroAv45 Imaging Research-in Alzheimer's Disease
NCT01325259
Amyloid Beta-peptide 1-40 and Alzheimer's Disease
NCT02770482
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AD patients
Subject fulfilling the McKhann criteria for clinical probable AD
No interventions assigned to this group
Healthy elder persons
Healthy controls with abscence of any cognitive disorder
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitaire Ziekenhuizen KU Leuven
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof Dr Jos Tournoy
MD PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bart De Strooper
Role: PRINCIPAL_INVESTIGATOR
KU Leuven
Francesc Guix
Role: PRINCIPAL_INVESTIGATOR
KU Leuven
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UZ Leuven
Leuven, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Gonzales PA, Pisitkun T, Hoffert JD, Tchapyjnikov D, Star RA, Kleta R, Wang NS, Knepper MA. Large-scale proteomics and phosphoproteomics of urinary exosomes. J Am Soc Nephrol. 2009 Feb;20(2):363-79. doi: 10.1681/ASN.2008040406. Epub 2008 Dec 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
s54591
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.